You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
金斯瑞生物科技(01548.HK):預期中期除細胞療法業務外經調整淨利潤增長10.3%至20.9%
格隆匯 08-07 18:55

格隆匯8月7日丨金斯瑞生物科技(01548.HK)公佈,截至2022年6月30日止六個月,集團繼續加大人才投入。集團預期以股權結算的股份薪酬開支約為3390萬美元至3830萬美元,而2021年同期約為1450萬美元。集團將持續推行團隊建設與員工激勵的計劃。

除細胞療法業務之外的集團業務的經調整淨利潤保持穩定增長,預期增長約10.3%至20.9%。非細胞療法業務預期錄得經調整淨利潤約2900萬美元至3180萬美元,而2021年同期約為2630萬美元。增加主要源自集團CDMO及合成生物學業務盈利能力的持續提升。

整體而言,集團預期期間錄得經調整虧損約1.15億美元至1.366億美元,而2021年同期錄得經調整虧損約1.358億美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account